India Pharma Outlook Team | Wednesday, 24 September 2025
Marksans Pharma Ltd declared that its UK subsidiary, Relonchem Limited, has obtained the marketing authorization from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for moxonidine tablets in 200 mcg and 400 mcg strengths.
Moxonidine is a drug used in the treatment of hypertension, hence, innovation in the Relonchem portfolio will be more appealing not only in the UK market but also in the rest of Europe. Relonchem got the MHRA green light for oxybutynin hydrochloride oral solution, the product that is intended to be used for symptoms management of overactive bladder, earlier in June.
Meanwhile, Marksans Pharma is also making strides in the US market. Its subsidiary, Time-Cap Laboratories, was issued an Establishment Inspection Report by the USFDA for its New York facility on June 30.
On the financial front, Marksans Pharma reported a 34.3% year-on-year decline in consolidated net profit to Rs 58.3 crore in Q1 FY26, impacted by ramp-up costs, a one-time expected credit loss provision, and foreign exchange adjustments.
Also Read: Shilpa Medicare Receives EMA Nod for Rivaroxaban Films
Revenue increased by 5% to Rs 620 crore, driven by new launches in the US and easing input costs, while gross profit rose nearly 9%. EBITDA declined 22% to Rs 100 crore, with margins contracting to 16.1% compared with 21.7% in the same quarter last year.
Mark Saldanha, the Managing Director of Marksans Pharma, commented that although the quarter was seasonally weak, and the impact on profitability is a short term one, the company’s long-term growth path is not affected and is further affirmed by planned strategic expansions and the increasing product portfolio in important international markets.
